galmic: affects behaviors in seizure, pain, and forced-swim tests; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 24748735 |
| CHEMBL ID | 1187471 |
| MeSH ID | M0471004 |
| Synonym |
|---|
| galmic |
| bdbm50415433 |
| CHEMBL1187471 , |
| gtpl6119 |
| DTXSID201028623 |
| methyl (2s)-6-amino-2-[[(4r,11r,18r)-11-(cyclohexylmethylcarbamoyl)-18-(9h-fluoren-9-ylcarbamoyl)-4,7,11,14,18,21-hexamethyl-2,9,16-trioxo-6,13,20-trioxa-3,10,17,22,23,24-hexazatetracyclo[17.2.1.15,8.112,15]tetracosa-1(21),5(24),7,12(23),14,19(22)-hexaene |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Galanin receptor type 1 | Homo sapiens (human) | Ki | 34.2000 | 0.0000 | 0.0000 | 0.0001 | AID459286 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | Galanin receptor type 1 | Homo sapiens (human) |
| negative regulation of adenylate cyclase activity | Galanin receptor type 1 | Homo sapiens (human) |
| positive regulation of cytosolic calcium ion concentration | Galanin receptor type 1 | Homo sapiens (human) |
| positive regulation of transcription by RNA polymerase II | Galanin receptor type 1 | Homo sapiens (human) |
| positive regulation of cortisol secretion | Galanin receptor type 1 | Homo sapiens (human) |
| neuropeptide signaling pathway | Galanin receptor type 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| galanin receptor activity | Galanin receptor type 1 | Homo sapiens (human) |
| protein binding | Galanin receptor type 1 | Homo sapiens (human) |
| peptide hormone binding | Galanin receptor type 1 | Homo sapiens (human) |
| neuropeptide binding | Galanin receptor type 1 | Homo sapiens (human) |
| G protein-coupled peptide receptor activity | Galanin receptor type 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Galanin receptor type 1 | Homo sapiens (human) |
| membrane | Galanin receptor type 1 | Homo sapiens (human) |
| plasma membrane | Galanin receptor type 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID459295 | Binding affinity to rat GalR2 | 2010 | Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4 | Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery. |
| AID459286 | Binding affinity to human GalR1 | 2010 | Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4 | Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery. |
| AID1345954 | Human GAL1 receptor (Galanin receptors) | 2004 | Proceedings of the National Academy of Sciences of the United States of America, Jul-13, Volume: 101, Issue:28 | Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. |
| AID1345954 | Human GAL1 receptor (Galanin receptors) | 2005 | Neuropeptides, Jun, Volume: 39, Issue:3 | Galnon--a low-molecular weight ligand of the galanin receptors. |
| AID1345950 | Rat GAL2 receptor (Galanin receptors) | 2005 | Neuropeptides, Jun, Volume: 39, Issue:3 | Galanin receptor ligands. |
| AID1345950 | Rat GAL2 receptor (Galanin receptors) | 2004 | Proceedings of the National Academy of Sciences of the United States of America, Jul-13, Volume: 101, Issue:28 | Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (33.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||